CClinicalTrials.gg
Sign In
Active, not recruitingNCT06639711Updated Dec 9, 2024

Taurine Eye Drops May Prevent the Progression of Cataract

A Phase 1/2 interventional study of Taurine in Cataract, sponsored by University Of Anbar. Active, not recruiting at 1 site in Iraq. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by University Of Anbar · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 3 months after the study started (first participant enrolled Jul 2023, registered Oct 2024).
Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract.

This study could answer:

  • Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract?
  • The acceptance/ compliance of participants to taurine-containing eye drops.
  • Could long-term use of taurine-containing eye drops cause adverse effect(s)?

Participants will:

  • Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year.
  • Visit eye clinic every 3 months for assessment and visual examination.
  • Keep notes for their symptoms and their adherence to treatment.
02

Conditions studied

  • Cataract

Browse trials for

03

In context

Cataract

1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.

This study's enrollment of 50 is below the median of 80 across 1,155 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

University Of Anbar is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The presence of grade I or II senile cataract on one or two eyes.

Exclusion criteria

Exclusion Criteria:

  • clinical signs of glaucoma
  • history of amblyopia, eye surgery, argon or YAG laser eye treatment, or major eye trauma
  • history of iritis, retinal crystalline deposits, or optic nerve disease
  • visually significant fundus pathology
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Application of Taurine-containing Eye Drops

    Drug: Taurine

Interventions

  • DrugTaurine

    Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year

    Also known as: VIZILOTIN Eye Drops

06

What researchers measure

Primary outcomes

  1. Visual Acuity

    Time frame: 1 Year

07

Study locations

1 site
  • Al-Nahrain Eye Clinics
    Ramadi, Anbar 31001, Iraq
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06639711
Lead sponsor
University Of Anbar
Responsible party
Atheer Zgair (Asst. Prof. Dr. Atheer Zgair, University Of Anbar) — Principal investigator
First posted
Oct 15, 2024
Start date
Jul 10, 2023
Primary completion
Dec 20, 2024 (estimated)
Completion
Dec 20, 2024 (estimated)
Last update
Dec 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cataract→

Other studies from this sponsor

University Of Anbar

Start the discussion